Since a couple of months Peter Hovstadius is the new Chief Medical Officer at XNK Therapeutics, responsible for leading the medical development of the company's products. XNK operates in biotechnology and develops cell therapies (ATMP) using natural killer cells (NK cells) for cancer treatment.
